Integrated Investment Consultants LLC Has $3.27 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Integrated Investment Consultants LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 413.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 112,885 shares of the biopharmaceutical company's stock after acquiring an additional 90,910 shares during the quarter. Integrated Investment Consultants LLC's holdings in Pfizer were worth $3,267,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $29,000. Gladius Capital Management LP increased its position in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP acquired a new position in shares of Pfizer during the second quarter worth approximately $31,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer in the second quarter valued at approximately $34,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Daiwa America upgraded shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price on the stock. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Finally, Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus price target of $32.92.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Trading Up 0.5 %

PFE stock traded up $0.12 during midday trading on Thursday, hitting $25.06. 34,540,022 shares of the company's stock were exchanged, compared to its average volume of 38,472,801. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $142.03 billion, a PE ratio of 33.65, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. The stock's fifty day moving average price is $28.36 and its 200-day moving average price is $28.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. During the same quarter in the previous year, the business posted ($0.17) EPS. Pfizer's revenue for the quarter was up 31.2% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.70%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's dividend payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.